EMA Authorised: Ikervis (ciclosporin) — Santen Oy

View source ↗

Summary

The EMA authorised Ikervis (ciclosporin) for corneal diseases. The marketing authorization holder is Santen Oy, with a decision date of 27 February 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease
• Keratoconjunctivitis Sicca

Drugs mentioned

• Ikervis (ciclosporin ophthalmic emulsion)

Snippet

Status: Authorised. Therapeutic area: Corneal Diseases. MAH: Santen Oy. Decision date: 27/02/2023